文献速递肝病

G/P方案治疗NS5A抑制剂联合索磷布韦治疗失败的基因1型HCV患者

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
PubMed 文献 · Gastroenterology · 2019-08-08

一项3b期开放标签随机研究纳入177例既往索磷布韦联合NS5A抑制剂治疗失败的基因1型HCV患者,无肝硬化者随机接受G/P 12周(A组78例)或16周(B组49例),代偿期肝硬化者随机接受G/P联合利巴韦林12周(C组21例)或G/P 16周(D组29例)。各组持续病毒学应答12周(SVR12)比例分别为90%、94%、86%和97%;G/P耐受性良好,利巴韦林增加不良事件但未提高疗效。

要点

  • 无肝硬化患者G/P 16周SVR12达94%,12周为90%。
  • 代偿期肝硬化患者G/P 16周SVR12达97%,联合利巴韦林12周为86%。
  • 利巴韦林增加不良事件但未增加疗效。

核心结论

  • 在既往索磷布韦联合NS5A抑制剂治疗失败的基因1型HCV患者中,G/P 16周治疗使超过90%的患者获得SVR12,包括代偿期肝硬化患者。
  • 利巴韦林增加不良事件但未增加疗效。

研究设计与样本

  • 3b期开放标签随机研究,纳入177例既往接受索磷布韦联合NS5A抑制剂治疗的慢性HCV基因1型感染患者。
  • 无肝硬化患者随机接受G/P 12周(A组n=78)或16周(B组n=49);代偿期肝硬化患者随机接受G/P联合利巴韦林12周(C组n=21)或G/P 16周(D组n=29)。
  • 主要终点为治疗结束后12周持续病毒学应答(SVR12)。

主要发现

  • A、B、C、D组SVR12比例分别为90%、94%、86%、97%。
  • 13例(7.3%)患者治疗失败,其中A组6例(7.9%)、B组3例(6.1%)、C组3例(6.1%)、D组1例(3.4%),均为基因1a型感染。
  • 多数患者基线存在NS5A耐药相关替换;治疗失败患者中分别有9例和10例出现NS3和NS5A治疗 emergent 耐药相关替换。
  • G/P耐受性良好;利巴韦林增加不良事件但未增加疗效。

关键数值与推荐

  • 无肝硬化:G/P 12周SVR12 90%(A组),G/P 16周SVR12 94%(B组)。
  • 代偿期肝硬化:G/P联合利巴韦林12周SVR12 86%(C组),G/P 16周SVR12 97%(D组)。

临床怎么用

  • 对于既往索磷布韦联合NS5A抑制剂治疗失败的基因1型HCV患者,可考虑G/P 16周方案,包括代偿期肝硬化患者。
  • 利巴韦林联合G/P未提高疗效且增加不良事件,原文未推荐常规加用利巴韦林。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomized trial of the safety and efficacy of 12 and 16 weeks of G/P, with or without ribavirin, in patients with HCV genotype 1 infection with treatment failure after sofosbuvir and an NS5A inhibitor. METHODS: We performed a phase 3b, open-label study of patients with chronic HCV genotype 1 infection who received previous treatment with sofosbuvir plus an NS5A inhibitor. Patients without cirrhosis were randomly assigned to groups that received G/P for 12 weeks (n = 78, group A) or 16 weeks (n = 49, group B). Patients with compensated cirrhosis were randomly assigned to groups that received G/P and ribavirin for 12 weeks (n = 21, group C) or G/P for 16 weeks (n = 29, group D). The primary end point was a sustained virologic response 12 weeks after treatment. Samples collected at baseline and at time of treatment failure were sequenced for resistance-associated substitutions in NS3 and NS5A. RESULTS: Of the 177 patients in the 4 groups, 81% were men, 79% had HCV genotype 1a infection, and 44% were black. Proportions of patients with sustained virologic response 12 weeks after treatment in groups A, B, C, and D were 90%, 94%, 86%, and 97%, respectively. The treatment failed in 13 (7.3%) patients with HCV genotype 1a infection, 6 (7.9%) in group A, 3 (6.1%) in group B, 3 (6.1%) in group C (6.1%), and 1 (3.4%) in group D. Most patients had baseline resistance-associated substitutions in NS5A. Treatment-emergent resistance-associated substitutions in NS3 and NS5A were observed in 9 and 10 patients with treatment failure, respectively. G/P was well tolerated. Ribavirin increased adverse events but did not increase efficacy. CONCLUSIONS: In a randomized study of patients with chronic HCV genotype 1 infection who received previous treatment with sofosbuvir plus an NS5A inhibitor, 16 weeks treatment with G/P produced sustained virologic response 12 weeks after treatment in >90% of patients, including those with compensated cirrhosis. ClinicalTrials.gov, Number: NCT03092375.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Lok AS, Sulkowski MS, Kort JJ, et al. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 2019. PMID: 31401140. doi:10.1053/j.gastro.2019.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。